Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience

Archive ouverte

Bernardor, Julie | Flammier, Sacha | Salles, Jean-Pierre | Amouroux, Cyril | Castanet, Mireille | Lienhardt, Anne | Martinerie, Laetitia | Damgov, Ivan | Linglart, Agnès | Bacchetta, Justine

Edité par CCSD ; Frontiers -

International audience. Background Cinacalcet is a calcimimetic approved in adults with primary hyperparathyroidism (PHPT). Few cases reports described its use in pediatric HPT, with challenges related to the risk of hypocalcemia, increased QT interval and drug interactions. In this study, we report the French experience in this setting. Methods We retrospectively analyzed data from 18 pediatric patients from 7 tertiary centers who received cinacalcet for PHPT. The results are presented as median (interquartile range). Results At a median age of 10.8 (2.0–14.4) years, 18 patients received cinacalcet for primary HPT ( N = 13 inactive CASR mutation, N = 1 CDC73 mutation, N = 1 multiple endocrine neoplasia type 1, N=3 unknown etiology). Cinacalcet was introduced at an estimated glomerular filtration rate (eGFR) of 120 (111–130) mL/min/1.73 m 2 , plasma calcium of 3.04 (2.96–3.14) mmol/L, plasma phosphate of 1.1 (1.0–1.3) mmol/L, age-standardized (z score) phosphate of −3.0 (−3.5;−1.9), total ALP of 212 (164–245) UI/L, 25-OHD of 37 (20–46) ng/L, age-standardized (z score) ALP of −2.4 (−3.7;−1.4), PTH of 75 (59–123) ng/L corresponding to 1.2 (1.0–2.3)-time the upper limit for normal (ULN). The starting daily dose of cinacalcet was 0.7 (0.6–1.0) mg/kg, with a maximum dose of 1.0 (0.9–1.4) mg/kg per day. With a follow-up of 2.2 (1.3–4.3) years on cinacalcet therapy, PTH and calcium significantly decreased to 37 (34–54) ng/L, corresponding to 0.8 (0.5–0.8) ULN ( p = 0.01), and 2.66 (2.55–2.90) mmol/L ( p = 0.002), respectively. In contrast, eGFR, 25-OHD, ALP and phosphate and urinary calcium levels remained stable. Nephrocalcinosis was not reported but one patient displayed nephrolithiasis. Cinacalcet was progressively withdrawn in three patients; no side effects were reported. Conclusions Cinacalcet in pediatric HPT can control hypercalcemia and PTH without significant side effects.

Consulter en ligne

Suggestions

Du même auteur

Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience

Archive ouverte | Bernardor, Julie | CCSD

International audience. Background Cinacalcet is a calcimimetic approved in adults with primary hyperparathyroidism (PHPT). Few cases reports described its use in pediatric HPT, with challenges related to the risk o...

Vitamin D and calcium intakes in general pediatric populations: A French expert consensus paper

Archive ouverte | Bacchetta, Justine | CCSD

International audience. OBJECTIVES: Nutritional vitamin D supplements are often used in general pediatrics. Here, the aim is to address vitamin D supplementation and calcium nutritional intakes in newborns, infants,...

Presenting features and molecular genetics of primary hyperparathyroidism in the paediatric population

Archive ouverte | El Allali, Yasmine | CCSD

International audience. Aim To describe the presenting features and molecular genetics of primary hyperparathyroidism (PHPT) in the paediatric population. Methods Retrospective study of 63 children diagnosed with pr...

Chargement des enrichissements...